Literature DB >> 19132784

Uveitis subtypes in a german interdisciplinary uveitis center--analysis of 1916 patients.

Eva Jakob1, Mirjam S Reuland, Friederike Mackensen, Nadine Harsch, Monika Fleckenstein, Hanns-Martin Lorenz, Regina Max, Matthias D Becker.   

Abstract

OBJECTIVE: Studies on the epidemiology of uveitis are rare and cohorts are small. We analyzed the frequencies of classified forms of uveitis in all patients at our center.
METHODS: We studied 1916 consecutive patients with inflammatory eye disease. Data were analyzed regarding associated systemic disease, infection, ocular syndromes, anatomic localization, age, and sex.
RESULTS: In 59.1% of patients, a classified form of uveitis was observed: associated systemic diseases in 43.7%, the most frequent ones sarcoidosis (17.4%) and ankylosing spondylitis (16.8%); ocular syndromes in 34.3%, the most frequent HLA-B27-positive anterior uveitis (AU; 35.1%) and Fuchs uveitis syndrome (FUS; 34.3%); and infections in 22.4%, the most frequent herpetic infections (46.1%) and toxoplasmosis (31.5%). We found AU in 45.4% of patients (15.4% HLA-B27-positive AU and 11.3% FUS), intermediate uveitis in 22.9% (unclassified 53.7% and multiple sclerosis 10.3%), and posterior uveitis in 13.5% (24.7% toxoplasmosis). Panuveitis was diagnosed in 6.2% of cases (Behçet's disease 12.6%; sarcoidosis 10.9%). The remaining 12.0% of cases showed extrauveal manifestations (scleritis, episcleritis, keratitis, optic neuritis, myositis, and orbital inflammation).
CONCLUSION: We describe the largest cohort to date of consecutive patients from a specialized uveitis center. The high frequency of classified disease, nearly 60% in our clinic, shows the usefulness of an interdisciplinary approach, oriented on anatomic presentation.

Entities:  

Mesh:

Year:  2009        PMID: 19132784     DOI: 10.3899/jrheum.080102

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  57 in total

1.  Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis.

Authors:  Allison R Loh; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2010-10       Impact factor: 5.258

Review 2.  Orbital and anterior visual pathway infection and inflammation.

Authors:  Roel De Wyngaert; Ingele Casteels; Philippe Demaerel
Journal:  Neuroradiology       Date:  2009-02-17       Impact factor: 2.804

Review 3.  [What rheumatologists can learn from ophthalmologists].

Authors:  M D Becker; R Max; A Dimitriou; T Saurenmann; H-M Lorenz; A Jansen; S Lortz; J Grulich-Henn; M Weber
Journal:  Z Rheumatol       Date:  2018-08       Impact factor: 1.372

Review 4.  Toxoplasmosis in Germany.

Authors:  Uwe Pleyer; Uwe Gross; Dirk Schlüter; Henrik Wilking; Frank Seeber
Journal:  Dtsch Arztebl Int       Date:  2019-06-21       Impact factor: 5.594

5.  Do systemic steroids increase the risk of ocular complication in uveitis patients? Focus on a Italian referral center.

Authors:  Chiara Posarelli; Rosaria Talarico; Giovanna Vella; Andrea Passani; Marta Mosca; Michele Figus
Journal:  Clin Rheumatol       Date:  2019-06-06       Impact factor: 2.980

Review 6.  [Ocular sarcoidosis].

Authors:  C Springer-Wanner; T Brauns
Journal:  Z Rheumatol       Date:  2017-06       Impact factor: 1.372

Review 7.  [Ocular involvement in rheumatoid arthritis, connective tissue diseases and vasculitis].

Authors:  I Kötter; N Stübiger; C Deuter
Journal:  Z Rheumatol       Date:  2017-10       Impact factor: 1.372

8.  [Differential diagnosis of anterior uveitis].

Authors:  S Thurau; U Pleyer
Journal:  Ophthalmologe       Date:  2016-10       Impact factor: 1.059

9.  Reclassifying Idiopathic Uveitis: Lessons From a Tertiary Uveitis Center.

Authors:  Rene Y Choi; Erick Rivera-Grana; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2018-10-22       Impact factor: 5.258

Review 10.  [Uveitis in multiple sclerosis : Overview and perspectives].

Authors:  A L Hildebrandt; F Mackensen
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.